A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)

Oncotarget

Volumn 2, Issue 12, 2011, Pages 1244-1253

  Banerjee, Sangeeta Ray ^a   Pullambhatla, Mrudula ^a   Shallal, Hassan ^a   Lisok, Ala ^a   Mease, Ronnie C ^a   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bivalent urea inhibitor; Molecular imaging; Multivalency; Naaladase; Prostate specific membrane antigen (PSMA); SPECT imaging

Indexed keywords

DIAGNOSTIC AGENT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CLICK CHEMISTRY; DRUG ANTAGONISM; HUMAN; ISOTOPE LABELING; MALE; METHODOLOGY; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PROSTATE TUMOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CLICK CHEMISTRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; ISOTOPE LABELING; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, MOLECULAR; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84862883597     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.415     Document Type: Article

References (37)

1. Cancer Facts and Figures. American Cancer Society. 2011.
2. Ghosh A and Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91:528-539.
3. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS and Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007; 25:540-547.
4. Olson WC, Heston WD and Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007; 2:182-190.
5. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD and Olson WC. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003; 100:12590-12595.
6. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM and Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011; 108:9578-9582.
7. Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL and Babich JW. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011; 52:1087-1093.
8. Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC and Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008; 51:7933-7943.
9. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP and Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005; 11:4022-4028.
10. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL and Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69:6932-6940.
11. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC and Babich JW. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009; 52:347-357.
12. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP and Pomper MG. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]- 4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14:3036-3043.
13. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP and Pomper MG. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008; 51:4504- 4517.
14. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC and Pomper MG. 68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer. J Med Chem. 2010; 53:5333-5341.
15. Chandran SS, Banerjee SR, Mease RC, Pomper MG and Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther. 2008; 7:974-982.
16. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC and Pomper MG. Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen. Angewandte Chemie. 2011; 50:9167-9170.
17. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M and Wester HJ. Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin. 2004; 43:26-32.
18. Tweedle MF. Adventures in multivalency, the Harry S. Fischer memorial lecture CMR 2005; Evian, France. Contrast Media Mol Imaging. 2006; 1:2-9.
19. Brabez N, Lynch RM, Xu L, Gillies RJ, Chassaing G, Lavielle S and Hruby VJ. Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem. 2011; 54:7375-7384.
20. Liu W, Hao G, Long MA, Anthony T, Hsieh JT and Sun X. Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes. Angew Chem Int Ed Engl. 2009; 48:7346-7349.
21. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ and Frechet JM. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A. 2009; 106:685- 690.
22. Humblet V, Misra P, Bhushan KR, Nasr K, Ko YS, Tsukamoto T, Pannier N, Frangioni JV and Maison W. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem. 2009; 52:544-550.
23. Huisgen R. 1,3-Dipolar Cycloadditions. Past and Future. Angew Chem Int Ed. 1963; 2:565-598.
24. Rostovtsev VV, Green LG, Fokin VV and Sharpless KB. A stepwise huisgen cycloaddition process: copper(I)- catalyzed regioselective "ligation" of azides and terminal alkynes. Angewandte Chemie (International ed.) 2002; 41:2596-2599.
25. Zhou J, Neale JH, Pomper MG and Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005; 4:1015-1026.
26. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS and Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59:3192-3198.
27. Silver DA, Pellicer I, Fair WR, Heston WD and Cordon- Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3:81-85.
28. Kularatne SA, Wang K, Santhapuram HK and Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharmacol. 2009; 6:780-789.
29. Kularatne SA, Zhou Z, Yang J, Post CB and Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharmacol. 2009; 6:790-800.
30. Cho S, Mease R, Holt D, Dannals R, Eisenberger M, Rodriguez R, Carducci M, Rojas C, Slusher B and Pomper M. Initial clinical assessment of DCFBC-PET for metastatic prostate cancer (PCa). J Nucl Med (SNM Annual Meeting Abstract). 2011; 52 (Supplement 1):41.
31. Chen Y, Pullambhatla M, Byun Y, Foss CA, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC and Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine- 3-carbonyl)-amino]-pentyl}-urei do)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate Cancer. Clin Cancer Res. 2011.
32. Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Baidoo KE, Brechbiel MW, Mease RC and Pomper MG. Preclinical evaluation of 86Y-Labeled inhibitors of prostate specific membrane antigen. J Label Compd Radiopharm (19th International Symposium on Radiopharmaceutical Sciences meeting abstract) 2011; 54:S65.
33. Banerjee SR, Maresca KP, Francesconi L, Valliant J, Babich JW and Zubieta J. New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol. 2005; 32:1-20.
34. Ray S, Pullambhatla M, Falk A, Byun Y, Foss C, Nimmagadda S, Fox J, Mease R and Pomper M. 99mTc-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Nucl Med. (SNM Annual Meeting Abstract). 2011; 52 (Supplement 1): 293.
35. Kaiser E, Colescott RL, Bossinger CD and Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970; 34:595- 598.
36. Cheng Y and Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22:3099-3108.
37. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B and Neale JH. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004; 47:1729-1738